GSA Capital Partners LLP Purchases Shares of 64,771 Pulmonx Co. (NASDAQ:LUNG)

GSA Capital Partners LLP purchased a new stake in Pulmonx Co. (NASDAQ:LUNG) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 64,771 shares of the company’s stock, valued at approximately $537,000.

A number of other hedge funds also recently bought and sold shares of LUNG. Allspring Global Investments Holdings LLC raised its position in Pulmonx by 609.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock valued at $79,000 after purchasing an additional 7,316 shares in the last quarter. Sei Investments Co. raised its position in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after acquiring an additional 1,800 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Pulmonx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock worth $19,262,000 after acquiring an additional 11,417 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Pulmonx during the 1st quarter worth about $102,000. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Pulmonx by 4.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 35,720 shares of the company’s stock worth $332,000 after acquiring an additional 1,633 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Insider Buying and Selling

In related news, General Counsel David Aaron Lehman sold 5,765 shares of Pulmonx stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $6.69, for a total transaction of $38,567.85. Following the completion of the transaction, the general counsel now directly owns 203,348 shares of the company’s stock, valued at approximately $1,360,398.12. The trade was a 2.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $8.09, for a total value of $161,800.00. Following the transaction, the director now directly owns 1,111,974 shares of the company’s stock, valued at approximately $8,995,869.66. This represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,351 shares of company stock valued at $361,494. 5.70% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on LUNG shares. Canaccord Genuity Group raised their target price on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Wells Fargo & Company cut their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. Finally, Stifel Nicolaus dropped their price target on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Pulmonx currently has a consensus rating of “Moderate Buy” and an average price target of $14.67.

Pulmonx Stock Down 2.0 %

Pulmonx stock opened at $6.00 on Wednesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. Pulmonx Co. has a 1-year low of $5.46 and a 1-year high of $14.84. The company has a market cap of $236.93 million, a PE ratio of -4.08 and a beta of 0.68. The stock’s 50 day moving average price is $7.16 and its 200 day moving average price is $7.17.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.39 million during the quarter, compared to analysts’ expectations of $20.39 million. Pulmonx had a negative return on equity of 53.88% and a negative net margin of 72.01%. During the same period in the previous year, the firm posted ($0.39) earnings per share. On average, sell-side analysts predict that Pulmonx Co. will post -1.53 EPS for the current fiscal year.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.